<?xml version="1.0" encoding="UTF-8"?><measure><measureDetails><uuid>40280381-503f-a1fc-0151-10faa31927bf</uuid><title>Breast Cancer: Hormonal Therapy for Stage I (T1b)-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer</title><shortTitle>CMS140</shortTitle><emeasureid>140</emeasureid><guid>ac639794-cb3f-4f4f-8fa6-680300d5ed4e</guid><version>5.0.000</version><nqfid extension="0387" root="2.16.840.1.113883.3.560.1"/><period calenderYear="true" uuid="40280381-3d61-56a7-013e-6abd73f9507e"><startDate>00000101</startDate><stopDate>00001231</stopDate></period><steward id="83e9797c-adec-4446-8c35-3ffd5d981c66">PCPI(R) Foundation (PCPI[R])</steward><developers><developer id="d041e15c-a7a0-41b8-be5b-87340ecd14bc">American Medical Association (AMA)</developer><developer id="83e9797c-adec-4446-8c35-3ffd5d981c66">PCPI(R) Foundation (PCPI[R])</developer></developers><endorsement id="2.16.840.1.113883.3.560">National Quality Forum</endorsement><description>Percentage of female patients aged 18 years and older with Stage I (T1b) through IIIC, ER or PR positive breast cancer who were prescribed tamoxifen or aromatase inhibitor (AI) during the 12-month reporting period</description><copyright>Copyright 2015 American Society of Clinical Oncology, National Comprehensive Cancer Network Association and American Medical Association. All Rights Reserved.</copyright><disclaimer>The Measures are not clinical guidelines, do not establish a standard of medical care, and have not been tested for all potential applications. &#xD;
&#xD;
The Measures, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, eg, use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain. &#xD;
&#xD;
Commercial uses of the Measures require a license agreement between the user and the PCPI(R) Foundation (PCPI[R]), the American Medical Association (AMA), National Comprehensive Cancer Network (NCCN) or American Society of Clinical Oncology (ASCO).  Neither the AMA, nor NCCN, nor ASCO, nor the AMA-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI), now known as the PCPI, nor their members shall be responsible for any use of the Measures.&#xD;
&#xD;
AMA and PCPI encourage use of the Measures by other health care professionals, where appropriate.&#xD;
&#xD;
THE MEASURES AND SPECIFICATIONS ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND.&#xD;
&#xD;
Limited proprietary coding is contained in the Measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. The AMA, NCCN, ASCO, the PCPI and its members and former members of the AMA-PCPI disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT[R]) or other coding contained in the specifications. &#xD;
&#xD;
CPT(R) contained in the Measure specifications is copyright 2004-2015 American Medical Association. LOINC(R) is copyright 2004-2015 Regenstrief Institute, Inc. This material contains SNOMED CLINICAL TERMS (SNOMED CT[R]) copyright 2004-2015 International Health Terminology Standards Development Organisation (IHTSDO). ICD-10 is copyright 2015 World Health Organization. All Rights Reserved.&#xD;
&#xD;
Due to technical limitations, registered trademarks are indicated by (R) or [R].</disclaimer><scoring id="PROPOR">Proportion</scoring><types><type id="PROCESS">Process</type></types><componentMeasures/><itemCount/><stratification>None</stratification><riskAdjustment>None</riskAdjustment><aggregation>None</aggregation><rationale>Despite evidence suggesting the role of adjuvant endocrine therapy in lowering the risk of tumor recurrence, many female patients who should be receiving this therapy are not. &#xD;
&#xD;
This measure assesses whether patients with a certain stage of breast cancer [I (T1b) through IIIC] and ER/PR+ are currently receiving the therapy. &#xD;
&#xD;
There are allowable medical, patient, and system reasons to document instances in which a woman with Stage I (T1b) through IIIC, ER/PR+ may not be a candidate for the therapy.</rationale><recommendations>I. Women diagnosed with hormone receptor-positive breast cancer who are pre- or perimenopausal should be offered adjuvant endocrine therapy with:&#xD;
     a. Tamoxifen for an initial duration of 5 years.&#xD;
     b. After 5 years, women should receive additional therapy based on menopausal status.&#xD;
          i. If women are pre- or perimenopausal, or if menopausal status is unknown or cannot be determined, they should be offered continued tamoxifen for a total duration of 10 years. (Type: Evidence-Based, Evidence Quality: High, Strength of Recommendation: Strong)&#xD;
          ii. If women have become definitively postmenopausal, they should be offered continued tamoxifen for a total duration of 10 years or switching to up to 5 years of an aromatase inhibitor (AI), for a total duration of up to 10 years of adjuvant endocrine therapy. (Type: Evidence-Based, Evidence Quality for tamoxifen: High, Evidence Quality for AI: High, Strength of Recommendation: Strong)&#xD;
&#xD;
II. Women diagnosed with hormone receptor-positive breast cancer who are postmenopausal should be offered adjuvant endocrine therapy with one of the following options:&#xD;
     a. Tamoxifen for a duration of 10 years. (Type: Evidence-Based, Evidence Quality: High, Strength of Recommendation: Strong) Or&#xD;
     b. An AI for a duration of 5 years. There are insufficient data currently to recommend an AI for a duration of greater than 5 years. (Type: Evidence-Based, Evidence Quality: High, Strength of Recommendation: Strong) Or&#xD;
     c. Tamoxifen for an initial duration of 5 years, then switching to an AI for up to 5 years, for a total duration of up to 10 years of adjuvant endocrine therapy. (Type: Evidence-Based, Evidence Quality: High, Strength of Recommendation: Strong) Or&#xD;
     d. Tamoxifen for a duration of 2 to 3 years and switching to an AI for up to 5 years, for a total duration of up to 7 to 8 years of adjuvant endocrine therapy. (Type: Evidence-Based, Evidence Quality: High, Strength of Recommendation: Strong)&#xD;
&#xD;
III. Women who are postmenopausal and are intolerant of either tamoxifen or an AI should be offered the alternative type of adjuvant endocrine therapy.&#xD;
     a. If women have received an AI but discontinued treatment at less than 5 years, they may be offered tamoxifen for a total of 5 years. (Type: Informal consensus, Evidence Quality: Low, Strength of Recommendation: Weak)&#xD;
     b. If women have received tamoxifen for 2 to 3 years, they should be offered switching to an AI for up to 5 years, for a total duration of up to 7 to 8 years of adjuvant endocrine therapy. (Type: Evidence-Based, Evidence Quality: High, Strength of Recommendation: Strong)&#xD;
&#xD;
IV. Women who have received 5 years of tamoxifen as adjuvant endocrine therapy should be offered additional adjuvant endocrine treatment.&#xD;
     a. If women are postmenopausal, they should be offered continued tamoxifen for a total duration of 10 years or switching to up to 5 years AI, for a total duration of up to 10 years of adjuvant endocrine therapy. (Type: Evidence-Based, Evidence Quality: High, Strength of Recommendation: Strong)&#xD;
     b. If women are pre- or perimenopausal, or menopausal status cannot be ascertained, they should be offered 5 additional years of tamoxifen, for a total duration of 10 years of adjuvant endocrine therapy. (Type: Evidence-Based, Evidence Quality: High, Strength of Recommendation: Strong) (ASCO, 2014)&#xD;
&#xD;
Patients with invasive breast cancers that are ER- or PR-positive should be considered for adjuvant endocrine therapy regardless of patient age, lymph node status, or whether adjuvant chemotherapy is to be administered. (NCCN, 2015)&#xD;
&#xD;
The most firmly established adjuvant endocrine therapy is tamoxifen for both premenopausal and postmenopausal women. In women with ER-positive breast cancer, adjuvant tamoxifen decreases the annual odds of recurrence by 39% and the annual odds of death by 31% irrespective of the use of chemotherapy, patient age, menopausal status, or ALN status. In patients receiving both tamoxifen and chemotherapy, chemotherapy should be given first, followed by sequential tamoxifen. Prospective, randomized trials have demonstrated that 5 years of tamoxifen is more effective than 1 to 2 years of tamoxifen. (NCCN, 2015)&#xD;
&#xD;
Patients with lymph node involvement or with tumors greater than 1cm in diameter are appropriate candidates for adjuvant systemic therapy (category 1). For women with lymph node-negative, hormone receptor-negative tumors greater than 1 cm in diameter, chemotherapy is recommended (category 1). For those with lymph node-negative, hormone receptor-positive breast cancer tumors greater than 0.5 cm, the panel recommends endocrine therapy with the consideration of chemotherapy (category 1). (NCCN, 2015)</recommendations><improvementNotations>Higher score indicates better quality</improvementNotations><references><reference>Burstein HJ, Temin S, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update. J Clin Oncol. 2014;32(21):2255-2269. doi:10.1200/JCO.2013.54.2258 </reference><reference>National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Breast Cancer. Version 3.2015. Available at http://www.nccn.org.</reference></references><definitions>Prescribed - May include prescription given to the patient for tamoxifen or aromatase inhibitor (AI) at one or more visits in the 12-month period OR patient already taking tamoxifen or aromatase inhibitor (AI) as documented in the current medication list.</definitions><guidance>For the eCQM version of this measure, the initial population for this measure has been limited to patients with a first recorded breast cancer diagnosis within the past 5 years, as opposed to accounting for that patient population through the use of an exception (as is the case for claims implementation). The numerator captures patients who are ordered adjuvant tamoxifen or AI, or are already taking adjuvant tamoxifen or AI during the 12 month period. Date of breast cancer diagnosis is defined as date of pathologic diagnosis.&#xD;
&#xD;
The requirement of "Count &gt;=2 of Encounter, Performed" is to establish that the eligible professional has an existing relationship with the patient.&#xD;
&#xD;
The denominator exception "Clinical Trial Participant" data element should be specific to breast cancer. For instance, the patient should be participating in a clinical trial related to breast cancer treatment in order to meet the "Clinical Trial Participant" data element in the denominator exceptions. In the given example, the reason the patient did not receive an order for or is not taking tamoxifen or aromatase inhibitor is because she is in a clinical trial and may be receiving different treatments.</guidance><transmissionFormat>TBD</transmissionFormat><initialPopDescription>All female patients aged 18 years and older with a diagnosis of breast cancer</initialPopDescription><denominatorDescription>Equals Initial Population with Stage I (T1b) through IIIC, estrogen receptor (ER) or progesterone receptor (PR) positive breast cancer</denominatorDescription><denominatorExclusionsDescription>None</denominatorExclusionsDescription><numeratorDescription>Patients who were prescribed tamoxifen or aromatase inhibitor (AI) during the 12-month reporting period</numeratorDescription><numeratorExclusionsDescription>Not Applicable</numeratorExclusionsDescription><denominatorExceptionsDescription>- Documentation of medical reason(s) for not prescribing tamoxifen or aromatase inhibitor (eg, patient's disease has progressed to metastatic, patient is receiving a gonadotropin-releasing hormone analogue, patient has received oophorectomy, patient is receiving radiation or chemotherapy, patient's diagnosis date is within 120 days of the end of the 12 month reporting period, other medical reasons)&#xD;
- Documentation of patient reason(s) for not prescribing tamoxifen or aromatase inhibitor (eg, patient refusal, other patient reasons)&#xD;
- Documentation of system reason(s) for not prescribing tamoxifen or aromatase inhibitor (eg, patient is currently enrolled in a clinical trial, other system reasons)</denominatorExceptionsDescription><supplementalData>For every patient evaluated by this measure also identify payer, race, ethnicity and sex</supplementalData><qualityMeasureSet uuid="45d70cd3-4d49-437d-93c5-f2520dbea26a">None</qualityMeasureSet>
<finalizedDate value="201602180834-0600"/>
</measureDetails><supplementalDataElements><elementRef id="40280381-3d61-56a7-013e-6abd73f95079" name="ONC Administrative Sex"/><elementRef id="40280381-3d61-56a7-013e-6abd73f9507a" name="Race"/><elementRef id="40280381-3d61-56a7-013e-6abd73f9507b" name="Ethnicity"/><elementRef id="40280381-3d61-56a7-013e-6abd73f9507c" name="Payer"/></supplementalDataElements><riskAdjustmentVariables/><subTreeLookUp><subTree displayName="Occurrence A of $OVorF2FEncounter" instance="A" instanceOf="9E3E61F9-02B0-427A-8180-F6816064B2B2" qdmVariable="true" uuid="6817C2BD-E576-41CE-AB30-12EF672FE210"><relationalOp displayName="During" type="DURING"><setOp displayName="Union" type="union"><elementRef displayName="Office Visit : Encounter, Performed" id="40280381-3d61-56a7-013e-6abd73f95081" type="qdm"/><elementRef displayName="Face-to-Face Interaction : Encounter, Performed" id="40280381-3d61-56a7-013e-6abd73fb50a9" type="qdm"/></setOp><elementRef displayName="Measurement Period : Timing Element" id="40280381-3d61-56a7-013e-6abd73f9507e" type="qdm"/></relationalOp></subTree><subTree displayName="Age greater than or equal to 18 at MP" qdmVariable="false" uuid="FA67876D-F92F-402B-8D3A-280E9EEE7084"><functionalOp displayName="Age&gt;= 18 years at" operatorType="Greater Than or Equal To" quantity="18" type="AGE AT" unit="years"><elementRef displayName="Measurement Period : Timing Element" id="40280381-3d61-56a7-013e-6abd73f9507e" type="qdm"/></functionalOp></subTree><subTree displayName="Count greater than or equal to 2 of Union of Enc Perf OV PatProv during MP" qdmVariable="false" uuid="78F0DE8C-78D3-4F53-86E4-4B398017FF54"><functionalOp displayName="Count&gt;= 2 " operatorType="Greater Than or Equal To" quantity="2" type="COUNT"><relationalOp displayName="During" type="DURING"><setOp displayName="Union" type="union"><elementRef displayName="Office Visit : Encounter, Performed" id="40280381-3d61-56a7-013e-6abd73f95081" type="qdm"/><elementRef displayName="Patient Provider Interaction : Encounter, Performed" id="40280381-3d61-56a7-013e-6abd73f95083" type="qdm"/></setOp><elementRef displayName="Measurement Period : Timing Element" id="40280381-3d61-56a7-013e-6abd73f9507e" type="qdm"/></relationalOp></functionalOp></subTree><subTree displayName="Dx BreastCancer ER or PR Pos sat all SBE OccA OVorF2F SAOCWS OccA Dx" qdmVariable="false" uuid="E3E10F6E-AAB7-415F-BE65-AC0620D51D16"><functionalOp displayName="Satisfies All" type="SATISFIES ALL"><elementRef displayName="Breast Cancer ER or PR Positive : Diagnosis" id="0b6f593e-809e-4250-9971-e69d4536b609" type="qdm"/><relationalOp displayName="Starts Before End Of" type="SBE"><elementRef displayName="Breast Cancer ER or PR Positive : Diagnosis" id="0b6f593e-809e-4250-9971-e69d4536b609" type="qdm"/><subTreeRef displayName="Occurrence A of OVorF2FEncounter" id="6817C2BD-E576-41CE-AB30-12EF672FE210" type="subTree"/></relationalOp><relationalOp displayName="Starts After Or Concurrent With Start Of" type="SASORSCW"><elementRef displayName="Breast Cancer ER or PR Positive : Diagnosis" id="0b6f593e-809e-4250-9971-e69d4536b609" type="qdm"/><elementRef displayName="Occurrence A of Breast Cancer : Diagnosis" id="cc853cc5-502d-41e8-847f-db2894b36960" type="qdm"/></relationalOp></functionalOp></subTree><subTree displayName="Intersection of Proc Perf Clinical Staging sat any T0 T1mi sat any N1 N2" qdmVariable="false" uuid="057792BC-25D1-4A11-AD3B-20E6BE358CE7"><setOp displayName="Intersection" type="intersection"><functionalOp displayName="Satisfies Any" type="SATISFIES ANY"><elementRef displayName="Pathology Evaluation : Procedure, Performed" id="d1cc4d1d-b09d-41d5-9817-5c32932eafb1" type="qdm"/><elementRef displayName="Pathology Evaluation : Procedure, Performed" id="d1cc4d1d-b09d-41d5-9817-5c32932eafb1" type="qdm"><attribute attrUUID="e83045a0-a8d2-411e-8ea5-3ae9b680c829" mode="Value Set" name="result" qdmUUID="40280381-3d61-56a7-013e-6abd73fa5087"/></elementRef><elementRef displayName="Pathology Evaluation : Procedure, Performed" id="d1cc4d1d-b09d-41d5-9817-5c32932eafb1" type="qdm"><attribute attrUUID="736c8f3b-7fff-4fda-b05b-0a8d7b1ff31c" mode="Value Set" name="result" qdmUUID="40280381-3d61-56a7-013e-6abd73fa5088"/></elementRef><elementRef displayName="Pathology Evaluation : Procedure, Performed" id="d1cc4d1d-b09d-41d5-9817-5c32932eafb1" type="qdm"><attribute attrUUID="9def8932-e443-406b-a551-3502cf905d35" mode="Value Set" name="result" qdmUUID="40280381-3d61-56a7-013e-6abd73fa5089"/></elementRef><elementRef displayName="Pathology Evaluation : Procedure, Performed" id="d1cc4d1d-b09d-41d5-9817-5c32932eafb1" type="qdm"><attribute attrUUID="bae18495-3a7b-4cad-9674-eb436f6ff1be" mode="Value Set" name="result" qdmUUID="40280381-3d61-56a7-013e-6abd73fa508a"/></elementRef><elementRef displayName="Pathology Evaluation : Procedure, Performed" id="d1cc4d1d-b09d-41d5-9817-5c32932eafb1" type="qdm"><attribute attrUUID="e5577802-c8e2-4e63-83f5-608529c22198" mode="Value Set" name="result" qdmUUID="40280381-3d61-56a7-013e-6abd73fa508b"/></elementRef><elementRef displayName="Pathology Evaluation : Procedure, Performed" id="d1cc4d1d-b09d-41d5-9817-5c32932eafb1" type="qdm"><attribute attrUUID="03e3a860-496b-4d8a-aafa-1095afed631a" mode="Value Set" name="result" qdmUUID="40280381-3d61-56a7-013e-6abd73fa508c"/></elementRef></functionalOp><functionalOp displayName="Satisfies Any" type="SATISFIES ANY"><elementRef displayName="Pathology Evaluation : Procedure, Performed" id="d1cc4d1d-b09d-41d5-9817-5c32932eafb1" type="qdm"/><elementRef displayName="Pathology Evaluation : Procedure, Performed" id="d1cc4d1d-b09d-41d5-9817-5c32932eafb1" type="qdm"><attribute attrUUID="12d0f53b-890b-4078-b538-34ca1a9b2edf" mode="Value Set" name="result" qdmUUID="40280381-3d61-56a7-013e-6abd73fa508d"/></elementRef><elementRef displayName="Pathology Evaluation : Procedure, Performed" id="d1cc4d1d-b09d-41d5-9817-5c32932eafb1" type="qdm"><attribute attrUUID="951b670d-4f75-4d1d-95a1-d6e48bb02204" mode="Value Set" name="result" qdmUUID="40280381-3d61-56a7-013e-6abd73fa508e"/></elementRef><elementRef displayName="Pathology Evaluation : Procedure, Performed" id="d1cc4d1d-b09d-41d5-9817-5c32932eafb1" type="qdm"><attribute attrUUID="5afdf851-f5a7-4843-9746-9b854613849d" mode="Value Set" name="result" qdmUUID="40280381-3d61-56a7-013e-6abd73fa508f"/></elementRef><elementRef displayName="Pathology Evaluation : Procedure, Performed" id="d1cc4d1d-b09d-41d5-9817-5c32932eafb1" type="qdm"><attribute attrUUID="56caf338-4201-439e-a701-a58924cfabe8" mode="Value Set" name="result" qdmUUID="40280381-3d61-56a7-013e-6abd73fa5090"/></elementRef><elementRef displayName="Pathology Evaluation : Procedure, Performed" id="d1cc4d1d-b09d-41d5-9817-5c32932eafb1" type="qdm"><attribute attrUUID="5507ccfe-e616-4569-bf6c-6a708f89f017" mode="Value Set" name="result" qdmUUID="40280381-3d61-56a7-013e-6abd73fa5091"/></elementRef><elementRef displayName="Pathology Evaluation : Procedure, Performed" id="d1cc4d1d-b09d-41d5-9817-5c32932eafb1" type="qdm"><attribute attrUUID="7e85a8c5-90e3-4bc2-ba6a-be505c94fc6e" mode="Value Set" name="result" qdmUUID="40280381-3d61-56a7-013e-6abd73fa5098"/></elementRef></functionalOp></setOp></subTree><subTree displayName="Intersection of Proc Perf Clinical Staging sat any T2 T4 sat any N0 N2" qdmVariable="false" uuid="1E4E9EBC-DEBC-4F66-BF3B-40C9AFDA87BE"><setOp displayName="Intersection" type="intersection"><functionalOp displayName="Satisfies Any" type="SATISFIES ANY"><elementRef displayName="Pathology Evaluation : Procedure, Performed" id="d1cc4d1d-b09d-41d5-9817-5c32932eafb1" type="qdm"/><elementRef displayName="Pathology Evaluation : Procedure, Performed" id="d1cc4d1d-b09d-41d5-9817-5c32932eafb1" type="qdm"><attribute attrUUID="2ec502b9-64c3-4c13-a0cd-ee54b2003959" mode="Value Set" name="result" qdmUUID="40280381-3d61-56a7-013e-6abd73fa5093"/></elementRef><elementRef displayName="Pathology Evaluation : Procedure, Performed" id="d1cc4d1d-b09d-41d5-9817-5c32932eafb1" type="qdm"><attribute attrUUID="5483e108-c914-4041-bd54-53495597fd64" mode="Value Set" name="result" qdmUUID="40280381-3d61-56a7-013e-6abd73fa5094"/></elementRef><elementRef displayName="Pathology Evaluation : Procedure, Performed" id="d1cc4d1d-b09d-41d5-9817-5c32932eafb1" type="qdm"><attribute attrUUID="cff9da42-5218-49e3-bad6-3b956e7aaa48" mode="Value Set" name="result" qdmUUID="40280381-3d61-56a7-013e-6abd73fa5095"/></elementRef></functionalOp><functionalOp displayName="Satisfies Any" type="SATISFIES ANY"><elementRef displayName="Pathology Evaluation : Procedure, Performed" id="d1cc4d1d-b09d-41d5-9817-5c32932eafb1" type="qdm"/><elementRef displayName="Pathology Evaluation : Procedure, Performed" id="d1cc4d1d-b09d-41d5-9817-5c32932eafb1" type="qdm"><attribute attrUUID="472dc2a7-07f1-477e-9be2-cd5a7cebef62" mode="Value Set" name="result" qdmUUID="40280381-3d61-56a7-013e-6abd73fa5096"/></elementRef><elementRef displayName="Pathology Evaluation : Procedure, Performed" id="d1cc4d1d-b09d-41d5-9817-5c32932eafb1" type="qdm"><attribute attrUUID="feb633b3-5d9f-4930-8764-ec3e8750476a" mode="Value Set" name="result" qdmUUID="40280381-3d61-56a7-013e-6abd73fa508d"/></elementRef><elementRef displayName="Pathology Evaluation : Procedure, Performed" id="d1cc4d1d-b09d-41d5-9817-5c32932eafb1" type="qdm"><attribute attrUUID="d02c1bde-53b1-4f34-85ca-be8a5a418bbc" mode="Value Set" name="result" qdmUUID="40280381-3d61-56a7-013e-6abd73fa5098"/></elementRef></functionalOp></setOp></subTree><subTree displayName="Intersection of Sat all M0 Dx Union of N3 two Intersections and T1c N0 " qdmVariable="false" uuid="3549CD49-412B-4447-836E-F3E4C6C74B66"><setOp displayName="Intersection" type="intersection"><subTreeRef displayName="Proc Perf Clinical Staging sat all result M0 SBE OccAOVorF2F SAOCWS OccADx" id="83C8D7D2-0A5F-4020-AF87-968AF41DD20F" type="subTree"/><setOp displayName="Union" type="union"><subTreeRef displayName="Proc Performed Clinical Staging result N3" id="0A9F80FE-5AED-4FDF-8014-85DF85F9D543" type="subTree"/><subTreeRef displayName="Intersection of Proc Perf Clinical Staging sat any T0 T1mi sat any N1 N2" id="057792BC-25D1-4A11-AD3B-20E6BE358CE7" type="subTree"/><subTreeRef displayName="Intersection of Proc Perf Clinical Staging sat any T2 T4 sat any N0 N2" id="1E4E9EBC-DEBC-4F66-BF3B-40C9AFDA87BE" type="subTree"/><subTreeRef displayName="Intersection Proc Perf Path Eval sat any result T1b T1c N0" id="32E989EE-D145-4818-AFCE-5F6CBA8DF196" type="subTree"/></setOp></setOp></subTree><subTree displayName="Med Active Tamoxifen Aromatase overlaps Occ A OVorF2FEncounter" qdmVariable="false" uuid="8CE0EA15-39C2-40D9-9B0C-523E7304403E"><relationalOp displayName="Overlaps" type="Overlap"><elementRef displayName="Tamoxifen or Aromatase Inhibitor Therapy : Medication, Active" id="a26065ee-0cd5-49b9-b564-878f0eac2b64" type="qdm"/><subTreeRef displayName="Occurrence A of OVorF2FEncounter" id="6817C2BD-E576-41CE-AB30-12EF672FE210" type="subTree"/></relationalOp></subTree><subTree displayName="Med Order Tamoxifen or Aromatase Inhib during OVorF2FEncounter " qdmVariable="false" uuid="B1E23811-9117-4E59-9CDE-9EFE756BC12C"><relationalOp displayName="During" type="DURING"><elementRef displayName="Tamoxifen or Aromatase Inhibitor Therapy : Medication, Order" id="40280381-3d61-56a7-013e-6abd73fa5099" type="qdm"/><subTreeRef displayName="Occurrence A of OVorF2FEncounter" id="6817C2BD-E576-41CE-AB30-12EF672FE210" type="subTree"/></relationalOp></subTree><subTree displayName="Occ A Dx Breast Cancer less than or equal to 120 days SBE MP" qdmVariable="false" uuid="AD759F21-0DEE-4DBB-A9AE-998F2615C515"><relationalOp displayName="&lt;= 120 days Starts Before End Of" operatorType="Less Than or Equal To" quantity="120" type="SBE" unit="days"><elementRef displayName="Occurrence A of Breast Cancer : Diagnosis" id="cc853cc5-502d-41e8-847f-db2894b36960" type="qdm"/><elementRef displayName="Measurement Period : Timing Element" id="40280381-3d61-56a7-013e-6abd73f9507e" type="qdm"/></relationalOp></subTree><subTree displayName="OVorF2FEncounter" qdmVariable="true" uuid="9E3E61F9-02B0-427A-8180-F6816064B2B2"><relationalOp displayName="During" type="DURING"><setOp displayName="Union" type="union"><elementRef displayName="Office Visit : Encounter, Performed" id="40280381-3d61-56a7-013e-6abd73f95081" type="qdm"/><elementRef displayName="Face-to-Face Interaction : Encounter, Performed" id="40280381-3d61-56a7-013e-6abd73fb50a9" type="qdm"/></setOp><elementRef displayName="Measurement Period : Timing Element" id="40280381-3d61-56a7-013e-6abd73f9507e" type="qdm"/></relationalOp></subTree><subTree displayName="Patient Characteristic Sex Female" qdmVariable="false" uuid="945D5EE1-CB23-4A0E-A482-55CD04F140E3"><elementRef displayName="Female : Patient Characteristic Sex" id="40280381-3d61-56a7-013e-6abd73f95084" type="qdm"/></subTree><subTree displayName="Proc Perf Bilateral Oophorectomy SBE OccA of OVorF2FEncounter" qdmVariable="false" uuid="C0B9AB29-78AA-4C6E-ADA2-A8C21E482A03"><relationalOp displayName="Starts Before End Of" type="SBE"><elementRef displayName="Bilateral Oophorectomy : Procedure, Performed" id="40280381-3d61-56a7-013e-6abd73fb50a1" type="qdm"/><subTreeRef displayName="Occurrence A of OVorF2FEncounter" id="6817C2BD-E576-41CE-AB30-12EF672FE210" type="subTree"/></relationalOp></subTree><subTree displayName="Proc Perf Chemotherapy during MP" qdmVariable="false" uuid="E47CE59F-5F63-4CDA-B3CA-5F8452812D06"><relationalOp displayName="During" type="DURING"><elementRef displayName="Chemotherapy : Procedure, Performed" id="40280381-3d61-56a7-013e-6abd73fb50a5" type="qdm"/><elementRef displayName="Measurement Period : Timing Element" id="40280381-3d61-56a7-013e-6abd73f9507e" type="qdm"/></relationalOp></subTree><subTree displayName="Proc Perf Clinical Staging sat all result M0 SBE OccAOVorF2F SAOCWS OccADx" qdmVariable="false" uuid="83C8D7D2-0A5F-4020-AF87-968AF41DD20F"><functionalOp displayName="Satisfies All" type="SATISFIES ALL"><elementRef displayName="Pathology Evaluation : Procedure, Performed" id="d1cc4d1d-b09d-41d5-9817-5c32932eafb1" type="qdm"/><relationalOp displayName="Starts Before End Of" type="SBE"><elementRef displayName="Pathology Evaluation : Procedure, Performed" id="d1cc4d1d-b09d-41d5-9817-5c32932eafb1" type="qdm"><attribute attrUUID="8cab0281-6af0-4ac1-ba63-146cd166a9fc" mode="Value Set" name="result" qdmUUID="40280381-3d61-56a7-013e-6abd73fa5092"/></elementRef><subTreeRef displayName="Occurrence A of OVorF2FEncounter" id="6817C2BD-E576-41CE-AB30-12EF672FE210" type="subTree"/></relationalOp><relationalOp displayName="Starts After Or Concurrent With Start Of" type="SASORSCW"><elementRef displayName="Pathology Evaluation : Procedure, Performed" id="d1cc4d1d-b09d-41d5-9817-5c32932eafb1" type="qdm"/><elementRef displayName="Occurrence A of Breast Cancer : Diagnosis" id="cc853cc5-502d-41e8-847f-db2894b36960" type="qdm"/></relationalOp></functionalOp></subTree><subTree displayName="Proc Perf Radiation Therapy II during MP" qdmVariable="false" uuid="30ADD0C1-E9D9-4F1F-83D8-796A815F5DB5"><relationalOp displayName="During" type="DURING"><elementRef displayName="Radiation Therapy II : Procedure, Performed" id="40280381-3d61-56a7-013e-6abd73fb50aa" type="qdm"/><elementRef displayName="Measurement Period : Timing Element" id="40280381-3d61-56a7-013e-6abd73f9507e" type="qdm"/></relationalOp></subTree><subTree displayName="Proc Performed Clinical Staging result N3" qdmVariable="false" uuid="0A9F80FE-5AED-4FDF-8014-85DF85F9D543"><elementRef displayName="Pathology Evaluation : Procedure, Performed" id="d1cc4d1d-b09d-41d5-9817-5c32932eafb1" type="qdm"><attribute attrUUID="bd5041a8-59cf-44a1-8f4b-9ebcc5dcde9e" mode="Value Set" name="result" qdmUUID="40280381-3d61-56a7-013e-6abd73fa5097"/></elementRef></subTree><subTree displayName="Union of 7 Exception elements overlaps Occ A of OVorF2FEncounter" qdmVariable="false" uuid="2560A2DF-E45D-427B-89DF-D5DBA7FD72D9"><relationalOp displayName="Overlaps" type="Overlap"><setOp displayName="Union" type="union"><elementRef displayName="Tamoxifen or Aromatase Inhibitor Therapy Ingredient : Medication, Allergy" id="8b698eb2-2f63-4495-a22c-dc566edbeaa3" type="qdm"/><elementRef displayName="Allergy to Tamoxifen or Aromatase Inhibitor Therapy : Diagnosis" id="e54401a2-0ba5-4130-b5b0-260c4cc32292" type="qdm"/><elementRef displayName="Tamoxifen or Aromatase Inhibitor Therapy : Medication, Intolerance" id="46b3f49f-ce3e-48ef-97dc-dccad8f80e29" type="qdm"/><elementRef displayName="Intolerance to Tamoxifen or Aromatase Inhibitor Therapy : Diagnosis" id="8072c8ea-db65-40bc-bbd5-435cfa6b23f6" type="qdm"/><elementRef displayName="Gonadotropin-Releasing Hormone Analogue Medication : Medication, Active" id="db7aa14a-c1d4-4b00-bf8b-83f19979fd62" type="qdm"/><elementRef displayName="Metastatic Sites Common to Breast Cancer : Diagnosis" id="fca47a7b-1038-4a81-ac0b-eabbdba802ec" type="qdm"/><elementRef displayName="Clinical Trial Participant : Patient Characteristic Clinical Trial Participant" id="411bab6d-e898-49a9-9285-434e4386911b" type="qdm"/></setOp><subTreeRef displayName="Occurrence A of OVorF2FEncounter" id="6817C2BD-E576-41CE-AB30-12EF672FE210" type="subTree"/></relationalOp></subTree><subTree displayName="Union of Med Order Med Active Tamoxifen Aromatase for Num" qdmVariable="false" uuid="302F6959-1735-4AAB-B188-9769F5FF5B2D"><setOp displayName="Union" type="union"><subTreeRef displayName="Med Order Tamoxifen or Aromatase Inhib during OVorF2FEncounter " id="B1E23811-9117-4E59-9CDE-9EFE756BC12C" type="subTree"/><subTreeRef displayName="Med Active Tamoxifen Aromatase overlaps Occ A OVorF2FEncounter" id="8CE0EA15-39C2-40D9-9B0C-523E7304403E" type="subTree"/></setOp></subTree><subTree displayName="Union of Med Order not done Tamox Aromatase starts during OccA of OVorF2F" qdmVariable="false" uuid="D1987A74-1A7D-4683-9585-DE35EE3EC0F0"><relationalOp displayName="Starts During" type="SDU"><setOp displayName="Union" type="union"><elementRef displayName="Tamoxifen or Aromatase Inhibitor Therapy Ingredient : Medication, Order" id="e0a44fb3-6377-4950-859a-1ccadfc9c686" type="qdm"><attribute attrUUID="d6caf6d6-bdc1-4437-8b19-2268b804d08a" mode="Value Set" name="negation rationale" qdmUUID="40280381-3d61-56a7-013e-6abd73fb50a6"/></elementRef><elementRef displayName="Tamoxifen or Aromatase Inhibitor Therapy Ingredient : Medication, Order" id="e0a44fb3-6377-4950-859a-1ccadfc9c686" type="qdm"><attribute attrUUID="54c75fa5-9f45-4892-8928-d903cca2ba28" mode="Value Set" name="negation rationale" qdmUUID="40280381-3d61-56a7-013e-6abd73fb50a7"/></elementRef><elementRef displayName="Tamoxifen or Aromatase Inhibitor Therapy Ingredient : Medication, Order" id="e0a44fb3-6377-4950-859a-1ccadfc9c686" type="qdm"><attribute attrUUID="fbaf27e1-c434-45d3-ab37-a0da79c0c6bf" mode="Value Set" name="negation rationale" qdmUUID="40280381-3d61-56a7-013e-6abd73fb50a8"/></elementRef></setOp><subTreeRef displayName="Occurrence A of OVorF2FEncounter" id="6817C2BD-E576-41CE-AB30-12EF672FE210" type="subTree"/></relationalOp></subTree><subTree displayName="FIRST Dx Breast Cancer less than or equal to 5 yrs SBE OccA OVorF2F" qdmVariable="false" uuid="83499891-A9D7-4EBD-BC57-5AC54761F805"><relationalOp displayName="&lt;= 5 years Starts Before End Of" operatorType="Less Than or Equal To" quantity="5" type="SBE" unit="years"><functionalOp displayName="First" type="FIRST"><elementRef displayName="Occurrence A of Breast Cancer : Diagnosis" id="cc853cc5-502d-41e8-847f-db2894b36960" type="qdm"/></functionalOp><subTreeRef displayName="Occurrence A of OVorF2FEncounter" id="6817C2BD-E576-41CE-AB30-12EF672FE210" type="subTree"/></relationalOp></subTree><subTree displayName="Intersection Proc Perf Path Eval sat any result T1b T1c N0" qdmVariable="false" uuid="32E989EE-D145-4818-AFCE-5F6CBA8DF196"><setOp displayName="Intersection" type="intersection"><functionalOp displayName="Satisfies Any" type="SATISFIES ANY"><elementRef displayName="Pathology Evaluation : Procedure, Performed" id="d1cc4d1d-b09d-41d5-9817-5c32932eafb1" type="qdm"/><elementRef displayName="Pathology Evaluation : Procedure, Performed" id="d1cc4d1d-b09d-41d5-9817-5c32932eafb1" type="qdm"><attribute attrUUID="458858e9-0743-4778-8a28-c0cecfd466c6" mode="Value Set" name="result" qdmUUID="40280381-3d61-56a7-013e-6abd73fa508a"/></elementRef><elementRef displayName="Pathology Evaluation : Procedure, Performed" id="d1cc4d1d-b09d-41d5-9817-5c32932eafb1" type="qdm"><attribute attrUUID="a5099f9f-6d39-422d-a8ce-420ebfd86fd8" mode="Value Set" name="result" qdmUUID="40280381-3d61-56a7-013e-6abd73fa508b"/></elementRef></functionalOp><elementRef displayName="Pathology Evaluation : Procedure, Performed" id="d1cc4d1d-b09d-41d5-9817-5c32932eafb1" type="qdm"><attribute attrUUID="bfaf03e8-a2e3-4b90-8e5e-30dd9e82ff2a" mode="Value Set" name="result" qdmUUID="40280381-3d61-56a7-013e-6abd73fa5096"/></elementRef></setOp></subTree></subTreeLookUp><measureGrouping><group sequence="1"><clause displayName="Initial Population 1" type="initialPopulation" uuid="44C7DE90-00EA-425D-BDB9-0269CE8827F6"><logicalOp displayName="AND" type="and"><subTreeRef displayName="FIRST Dx Breast Cancer less than or equal to 5 yrs SBE OccA OVorF2F" id="83499891-A9D7-4EBD-BC57-5AC54761F805" type="subTree"/><subTreeRef displayName="Age greater than or equal to 18 at MP" id="FA67876D-F92F-402B-8D3A-280E9EEE7084" type="subTree"/><subTreeRef displayName="Count greater than or equal to 2 of Union of Enc Perf OV PatProv during MP" id="78F0DE8C-78D3-4F53-86E4-4B398017FF54" type="subTree"/><subTreeRef displayName="Patient Characteristic Sex Female" id="945D5EE1-CB23-4A0E-A482-55CD04F140E3" type="subTree"/></logicalOp></clause><clause displayName="Denominator 1" type="denominator" uuid="3265FD45-5A60-4B37-A8A5-5BE2772D53D7"><logicalOp displayName="AND" type="and"><subTreeRef displayName="Dx BreastCancer ER or PR Pos sat all SBE OccA OVorF2F SAOCWS OccA Dx" id="E3E10F6E-AAB7-415F-BE65-AC0620D51D16" type="subTree"/><subTreeRef displayName="Intersection of Sat all M0 Dx Union of N3 two Intersections and T1c N0 " id="3549CD49-412B-4447-836E-F3E4C6C74B66" type="subTree"/></logicalOp></clause><clause displayName="Denominator Exceptions 1" type="denominatorExceptions" uuid="7258DC78-65AD-43DC-95FD-8D3BA030A1D5"><logicalOp displayName="OR" type="or"><subTreeRef displayName="Occ A Dx Breast Cancer less than or equal to 120 days SBE MP" id="AD759F21-0DEE-4DBB-A9AE-998F2615C515" type="subTree"/><subTreeRef displayName="Proc Perf Radiation Therapy II during MP" id="30ADD0C1-E9D9-4F1F-83D8-796A815F5DB5" type="subTree"/><subTreeRef displayName="Proc Perf Chemotherapy during MP" id="E47CE59F-5F63-4CDA-B3CA-5F8452812D06" type="subTree"/><subTreeRef displayName="Proc Perf Bilateral Oophorectomy SBE OccA of OVorF2FEncounter" id="C0B9AB29-78AA-4C6E-ADA2-A8C21E482A03" type="subTree"/><subTreeRef displayName="Union of Med Order not done Tamox Aromatase starts during OccA of OVorF2F" id="D1987A74-1A7D-4683-9585-DE35EE3EC0F0" type="subTree"/><subTreeRef displayName="Union of 7 Exception elements overlaps Occ A of OVorF2FEncounter" id="2560A2DF-E45D-427B-89DF-D5DBA7FD72D9" type="subTree"/></logicalOp></clause><clause displayName="Numerator 2" type="numerator" uuid="50415DF5-6B2B-4EC4-8226-C04FC0B91E1E"><logicalOp displayName="AND" type="and"><subTreeRef displayName="Union of Med Order Med Active Tamoxifen Aromatase for Num" id="302F6959-1735-4AAB-B188-9769F5FF5B2D" type="subTree"/></logicalOp></clause><clause displayName="denominatorExclusions" type="denominatorExclusions" uuid="9c46db33-1639-4561-b0f7-9b22a48171c6"><logicalOp displayName="AND" type="and"/></clause><clause displayName="numeratorExclusions" type="numeratorExclusions" uuid="5793dfd3-49a4-4e52-81ad-46f3c35c8cba"><logicalOp displayName="AND" type="and"/></clause><clause displayName="stratum" type="stratum" uuid="8dd84ac2-31ba-48c6-8c7c-62e06a1f021a"/></group></measureGrouping><elementLookUp><qdm datatype="Diagnosis" id="e54401a2-0ba5-4130-b5b0-260c4cc32292" name="Allergy to Tamoxifen or Aromatase Inhibitor Therapy" oid="2.16.840.1.113883.3.526.3.1317" suppDataElement="false" taxonomy="Grouping" uuid="e54401a2-0ba5-4130-b5b0-260c4cc32292" version="1.0"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="Procedure, Performed" id="40280381-3d61-56a7-013e-6abd73fb50a1" name="Bilateral Oophorectomy" oid="2.16.840.1.113883.3.526.3.471" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6abd73fb50a1" version="1"/><qdm datatype="Patient Characteristic Birthdate" id="2878eabc-563e-494b-b72f-e95d0cae8feb" name="Birthdate" oid="21112-8" suppDataElement="false" taxonomy="SNOMED-CT" uuid="2878eabc-563e-494b-b72f-e95d0cae8feb" version="1.0"/><qdm datatype="Diagnosis" id="cc853cc5-502d-41e8-847f-db2894b36960" instance="Occurrence A" name="Breast Cancer" oid="2.16.840.1.113883.3.526.3.389" suppDataElement="false" taxonomy="Grouping" uuid="cc853cc5-502d-41e8-847f-db2894b36960" version="1.0"/><qdm datatype="Diagnosis" id="0b6f593e-809e-4250-9971-e69d4536b609" name="Breast Cancer ER or PR Positive" oid="2.16.840.1.113883.3.526.3.1303" suppDataElement="false" taxonomy="Grouping" uuid="0b6f593e-809e-4250-9971-e69d4536b609" version="1.0"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="attribute" id="40280381-3d61-56a7-013e-6abd73fa5087" name="Breast Cancer Primary Tumor Size T0" oid="2.16.840.1.113883.3.526.3.1304" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6abd73fa5087" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="attribute" id="40280381-3d61-56a7-013e-6abd73fa5088" name="Breast Cancer Primary Tumor Size T1" oid="2.16.840.1.113883.3.526.3.1305" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6abd73fa5088" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="attribute" id="40280381-3d61-56a7-013e-6abd73fa5089" name="Breast Cancer Primary Tumor Size T1a" oid="2.16.840.1.113883.3.526.3.1164" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6abd73fa5089" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="attribute" id="40280381-3d61-56a7-013e-6abd73fa508a" name="Breast Cancer Primary Tumor Size T1b" oid="2.16.840.1.113883.3.526.3.1270" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6abd73fa508a" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="attribute" id="40280381-3d61-56a7-013e-6abd73fa508b" name="Breast Cancer Primary Tumor Size T1c" oid="2.16.840.1.113883.3.526.3.1306" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6abd73fa508b" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="attribute" id="40280381-3d61-56a7-013e-6abd73fa508c" name="Breast Cancer Primary Tumor Size T1mi" oid="2.16.840.1.113883.3.526.3.1197" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6abd73fa508c" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="attribute" id="40280381-3d61-56a7-013e-6abd73fa5093" name="Breast Cancer Primary Tumor Size T2" oid="2.16.840.1.113883.3.526.3.1307" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6abd73fa5093" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="attribute" id="40280381-3d61-56a7-013e-6abd73fa5094" name="Breast Cancer Primary Tumor Size T3" oid="2.16.840.1.113883.3.526.3.1308" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6abd73fa5094" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="attribute" id="40280381-3d61-56a7-013e-6abd73fa5095" name="Breast Cancer Primary Tumor Size T4" oid="2.16.840.1.113883.3.526.3.1309" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6abd73fa5095" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="attribute" id="40280381-3d61-56a7-013e-6abd73fa5096" name="Breast Cancer Regional Lymph Node Status N0" oid="2.16.840.1.113883.3.526.3.1310" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6abd73fa5096" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="attribute" id="40280381-3d61-56a7-013e-6abd73fa508d" name="Breast Cancer Regional Lymph Node Status N1" oid="2.16.840.1.113883.3.526.3.1329" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6abd73fa508d" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="attribute" id="40280381-3d61-56a7-013e-6abd73fa5098" name="Breast Cancer Regional Lymph Node Status N2" oid="2.16.840.1.113883.3.526.3.1313" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6abd73fa5098" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="attribute" id="40280381-3d61-56a7-013e-6abd73fa5097" name="Breast Cancer Regional Lymph Node Status N3" oid="2.16.840.1.113883.3.526.3.1314" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6abd73fa5097" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="attribute" id="40280381-3d61-56a7-013e-6abd73fa508e" name="Breast Cancer Regional Lymph Node Status pN1a" oid="2.16.840.1.113883.3.526.3.1311" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6abd73fa508e" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="attribute" id="40280381-3d61-56a7-013e-6abd73fa508f" name="Breast Cancer Regional Lymph Node Status pN1b" oid="2.16.840.1.113883.3.526.3.1330" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6abd73fa508f" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="attribute" id="40280381-3d61-56a7-013e-6abd73fa5090" name="Breast Cancer Regional Lymph Node Status pN1c" oid="2.16.840.1.113883.3.526.3.1331" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6abd73fa5090" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="attribute" id="40280381-3d61-56a7-013e-6abd73fa5091" name="Breast Cancer Regional Lymph Node Status pN1mi" oid="2.16.840.1.113883.3.526.3.1312" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6abd73fa5091" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="attribute" id="40280381-3d61-56a7-013e-6abd73fa5092" name="Breast Distant Metastasis Status M0" oid="2.16.840.1.113883.3.526.3.1302" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6abd73fa5092" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="Procedure, Performed" id="40280381-3d61-56a7-013e-6abd73fb50a5" name="Chemotherapy" oid="2.16.840.1.113883.3.526.3.485" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6abd73fb50a5" version="1"/><qdm datatype="Procedure, Performed" id="d1cc4d1d-b09d-41d5-9817-5c32932eafb1" name="Pathology Evaluation" oid="2.16.840.1.113883.3.526.3.1098" suppDataElement="false" taxonomy="Grouping" uuid="d1cc4d1d-b09d-41d5-9817-5c32932eafb1" version="1.0"/><qdm datatype="Patient Characteristic Clinical Trial Participant" id="411bab6d-e898-49a9-9285-434e4386911b" name="Clinical Trial Participant" oid="2.16.840.1.113883.3.526.3.1125" suppDataElement="false" taxonomy="Grouping" uuid="411bab6d-e898-49a9-9285-434e4386911b" version="1.0"/><qdm codeSystemName="CDC NCHS" datatype="Patient Characteristic Ethnicity" id="40280381-3d61-56a7-013e-6abd73f9507b" name="Ethnicity" oid="2.16.840.1.114222.4.11.837" suppDataElement="true" taxonomy="CDCREC" uuid="40280381-3d61-56a7-013e-6abd73f9507b" version="1"/><qdm datatype="Patient Characteristic Expired" id="b0d61dc4-f238-4444-888c-e8e7b080314c" name="Expired" oid="419099009" suppDataElement="false" taxonomy="SNOMED-CT" uuid="b0d61dc4-f238-4444-888c-e8e7b080314c" version="1.0"/><qdm codeSystemName="National Committee for Quality Assurance" datatype="Encounter, Performed" id="40280381-3d61-56a7-013e-6abd73fb50a9" name="Face-to-Face Interaction" oid="2.16.840.1.113883.3.464.1003.101.12.1048" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6abd73fb50a9" version="1.0"/><qdm codeSystemName="National Quality Forum" datatype="Patient Characteristic Sex" id="40280381-3d61-56a7-013e-6abd73f95084" name="Female" oid="2.16.840.1.113883.3.560.100.2" suppDataElement="false" taxonomy="AdministrativeGender" uuid="40280381-3d61-56a7-013e-6abd73f95084" version="1"/><qdm datatype="Medication, Active" id="db7aa14a-c1d4-4b00-bf8b-83f19979fd62" name="Gonadotropin-Releasing Hormone Analogue Medication" oid="2.16.840.1.113883.3.526.3.1316" suppDataElement="false" taxonomy="Grouping" uuid="db7aa14a-c1d4-4b00-bf8b-83f19979fd62" version="1.0"/><qdm datatype="Diagnosis" id="8072c8ea-db65-40bc-bbd5-435cfa6b23f6" name="Intolerance to Tamoxifen or Aromatase Inhibitor Therapy" oid="2.16.840.1.113883.3.526.3.1318" suppDataElement="false" taxonomy="Grouping" uuid="8072c8ea-db65-40bc-bbd5-435cfa6b23f6" version="1.0"/><qdm codeSystemName="National Quality Forum" datatype="Timing Element" id="40280381-3d61-56a7-013e-6abd73f9507e" name="Measurement Period" oid="2.16.840.1.113883.3.67.1.101.1.53" suppDataElement="false" taxonomy="NQF" uuid="40280381-3d61-56a7-013e-6abd73f9507e" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="attribute" id="40280381-3d61-56a7-013e-6abd73fb50a6" name="Medical Reason" oid="2.16.840.1.113883.3.526.3.1007" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6abd73fb50a6" version="1"/><qdm datatype="Diagnosis" id="fca47a7b-1038-4a81-ac0b-eabbdba802ec" name="Metastatic Sites Common to Breast Cancer" oid="2.16.840.1.113883.3.526.3.447" suppDataElement="false" taxonomy="Grouping" uuid="fca47a7b-1038-4a81-ac0b-eabbdba802ec" version="1.0"/><qdm codeSystemName="National Committee for Quality Assurance" datatype="Encounter, Performed" id="40280381-3d61-56a7-013e-6abd73f95081" name="Office Visit" oid="2.16.840.1.113883.3.464.1003.101.12.1001" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6abd73f95081" version="1"/><qdm codeSystemName="National Library of Medicine" datatype="Patient Characteristic Sex" id="40280381-3d61-56a7-013e-6abd73f95079" name="ONC Administrative Sex" oid="2.16.840.1.113762.1.4.1" suppDataElement="true" taxonomy="AdministrativeGender" uuid="40280381-3d61-56a7-013e-6abd73f95079" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="Encounter, Performed" id="40280381-3d61-56a7-013e-6abd73f95083" name="Patient Provider Interaction" oid="2.16.840.1.113883.3.526.3.1012" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6abd73f95083" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="attribute" id="40280381-3d61-56a7-013e-6abd73fb50a7" name="Patient Reason" oid="2.16.840.1.113883.3.526.3.1008" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6abd73fb50a7" version="1"/><qdm codeSystemName="PHDSC" datatype="Patient Characteristic Payer" id="40280381-3d61-56a7-013e-6abd73f9507c" name="Payer" oid="2.16.840.1.114222.4.11.3591" suppDataElement="true" taxonomy="SOP" uuid="40280381-3d61-56a7-013e-6abd73f9507c" version="1"/><qdm codeSystemName="CDC NCHS" datatype="Patient Characteristic Race" id="40280381-3d61-56a7-013e-6abd73f9507a" name="Race" oid="2.16.840.1.114222.4.11.836" suppDataElement="true" taxonomy="CDCREC" uuid="40280381-3d61-56a7-013e-6abd73f9507a" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="Procedure, Performed" id="40280381-3d61-56a7-013e-6abd73fb50aa" name="Radiation Therapy II" oid="2.16.840.1.113883.3.526.3.1339" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6abd73fb50aa" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="attribute" id="40280381-3d61-56a7-013e-6abd73fb50a8" name="System Reason" oid="2.16.840.1.113883.3.526.3.1009" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6abd73fb50a8" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="Medication, Order" id="40280381-3d61-56a7-013e-6abd73fa5099" name="Tamoxifen or Aromatase Inhibitor Therapy" oid="2.16.840.1.113883.3.526.3.1315" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6abd73fa5099" version="1"/><qdm datatype="Medication, Intolerance" id="46b3f49f-ce3e-48ef-97dc-dccad8f80e29" name="Tamoxifen or Aromatase Inhibitor Therapy" oid="2.16.840.1.113883.3.526.3.1315" suppDataElement="false" taxonomy="Grouping" uuid="46b3f49f-ce3e-48ef-97dc-dccad8f80e29" version="1.0"/><qdm datatype="Medication, Active" id="a26065ee-0cd5-49b9-b564-878f0eac2b64" name="Tamoxifen or Aromatase Inhibitor Therapy" oid="2.16.840.1.113883.3.526.3.1315" suppDataElement="false" taxonomy="Grouping" uuid="a26065ee-0cd5-49b9-b564-878f0eac2b64" version="1.0"/><qdm datatype="Medication, Allergy" id="8b698eb2-2f63-4495-a22c-dc566edbeaa3" name="Tamoxifen or Aromatase Inhibitor Therapy Ingredient" oid="2.16.840.1.113883.3.526.3.1487" suppDataElement="false" taxonomy="Grouping" uuid="8b698eb2-2f63-4495-a22c-dc566edbeaa3" version="1.0"/><qdm datatype="Medication, Order" id="e0a44fb3-6377-4950-859a-1ccadfc9c686" name="Tamoxifen or Aromatase Inhibitor Therapy Ingredient" oid="2.16.840.1.113883.3.526.3.1487" suppDataElement="false" taxonomy="Grouping" uuid="e0a44fb3-6377-4950-859a-1ccadfc9c686" version="1.0"/><qdm datatype="Diagnosis" id="a474c7ed-f86f-439b-beb0-5f8a51860fbf" name="Breast Cancer" oid="2.16.840.1.113883.3.526.3.389" suppDataElement="false" taxonomy="Grouping" uuid="a474c7ed-f86f-439b-beb0-5f8a51860fbf" version="1.0"/></elementLookUp></measure>